{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Seizures%2C+Focal&page=3",
    "query": {
      "condition": "Seizures, Focal",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 114,
    "total_pages": 12,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Seizures%2C+Focal&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Seizures%2C+Focal&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-05T05:52:00.646Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04903314",
      "title": "Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Partial Epilepsy"
      ],
      "interventions": [
        {
          "name": "Xcopri",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SK Life Science, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "2 Years to 18 Years"
      },
      "enrollment_count": 26,
      "start_date": "2021-05-27",
      "completion_date": "2025-11-06",
      "has_results": false,
      "last_update_posted_date": "2026-03-31",
      "last_synced_at": "2026-10-05T05:52:00.646Z",
      "location_count": 8,
      "location_summary": "Phoenix, Arizona • Bethesda, Maryland • Columbia, Missouri + 5 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Columbia",
          "state": "Missouri"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04903314"
    },
    {
      "nct_id": "NCT07505004",
      "title": "Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Focal Epilepsy"
      ],
      "interventions": [
        {
          "name": "40 mg/day vormatrogine for 12 weeks",
          "type": "DRUG"
        },
        {
          "name": "30 mg/day vormatrogine for 12 weeks",
          "type": "DRUG"
        },
        {
          "name": "20 mg/day vormatrogine for 12 weeks",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Praxis Precision Medicines",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 300,
      "start_date": "2026-01-29",
      "completion_date": "2027-05",
      "has_results": false,
      "last_update_posted_date": "2026-08-03",
      "last_synced_at": "2026-10-05T05:52:00.646Z",
      "location_count": 7,
      "location_summary": "Miami, Florida • Miami Lakes, Florida • Naples, Florida + 4 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        },
        {
          "city": "Naples",
          "state": "Florida"
        },
        {
          "city": "Marlboro",
          "state": "New Jersey"
        },
        {
          "city": "Niagara Falls",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07505004"
    },
    {
      "nct_id": "NCT00050947",
      "title": "Pediatric Epilepsy Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Epilepsy"
      ],
      "interventions": [
        {
          "name": "oxcarbazepine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "1 Month to 16 Years"
      },
      "enrollment_count": 94,
      "start_date": "2002-07",
      "completion_date": "2004-02",
      "has_results": false,
      "last_update_posted_date": "2011-11-23",
      "last_synced_at": "2026-10-05T05:52:00.646Z",
      "location_count": 25,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Madera, California + 22 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Madera",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00050947"
    },
    {
      "nct_id": "NCT05718817",
      "title": "An Open-label Study of XEN1101 in Epilepsy",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Focal Epilepsy",
        "Tonic-Clonic Seizures"
      ],
      "interventions": [
        {
          "name": "XEN1101",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Xenon Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 880,
      "start_date": "2023-04-25",
      "completion_date": "2033-06",
      "has_results": false,
      "last_update_posted_date": "2026-09-11",
      "last_synced_at": "2026-10-05T05:52:00.646Z",
      "location_count": 54,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 48 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05718817"
    },
    {
      "nct_id": "NCT04099342",
      "title": "Enhanced Spatial Targeting in ECT Utilizing FEAST",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Treatment Resistant Depression"
      ],
      "interventions": [
        {
          "name": "FEAST",
          "type": "DEVICE"
        },
        {
          "name": "FEAST RP",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "22 Years to 90 Years"
      },
      "enrollment_count": 20,
      "start_date": "2022-06-01",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-13",
      "last_synced_at": "2026-10-05T05:52:00.646Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04099342"
    },
    {
      "nct_id": "NCT00235755",
      "title": "Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Seizures"
      ],
      "interventions": [
        {
          "name": "Retigabine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 539,
      "start_date": "2005-12",
      "completion_date": "2008-04",
      "has_results": true,
      "last_update_posted_date": "2017-04-21",
      "last_synced_at": "2026-10-05T05:52:00.646Z",
      "location_count": 2,
      "location_summary": "Bethesda, Maryland • Dallas, Texas",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00235755"
    },
    {
      "nct_id": "NCT03283371",
      "title": "Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Epilepsy, Focal Seizures, Partial Seizures"
      ],
      "interventions": [
        {
          "name": "Natalizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 67,
      "start_date": "2018-03-20",
      "completion_date": "2020-11-18",
      "has_results": true,
      "last_update_posted_date": "2021-12-14",
      "last_synced_at": "2026-10-05T05:52:00.646Z",
      "location_count": 31,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 26 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03283371"
    },
    {
      "nct_id": "NCT02339376",
      "title": "Treating Deep Seizure Foci With Noninvasive Surface Brain Stimulation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Epilepsy, Temporal Lobe"
      ],
      "interventions": [
        {
          "name": "Low-frequency repetitive transcranial magnetic stimulation",
          "type": "DEVICE"
        },
        {
          "name": "High-frequency repetitive transcranial magnetic stimulation",
          "type": "DEVICE"
        },
        {
          "name": "Sham repetitive transcranial magnetic stimulation",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Beth Israel Deaconess Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 5,
      "start_date": "2015-01",
      "completion_date": "2021-03-10",
      "has_results": true,
      "last_update_posted_date": "2025-05-29",
      "last_synced_at": "2026-10-05T05:52:00.646Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02339376"
    },
    {
      "nct_id": "NCT00465517",
      "title": "A Randomized, Controlled Trial of Ganaxolone in Adult Uncontrolled Partial-Onset Seizures",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Partial Epilepsy",
        "Catamenial Epilepsy"
      ],
      "interventions": [
        {
          "name": "Ganaxolone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Marinus Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "18 Years to 69 Years"
      },
      "enrollment_count": 147,
      "start_date": "2007-02",
      "completion_date": "2008-11",
      "has_results": true,
      "last_update_posted_date": "2023-03-15",
      "last_synced_at": "2026-10-05T05:52:00.646Z",
      "location_count": 27,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 23 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00465517"
    },
    {
      "nct_id": "NCT04244175",
      "title": "A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Seizures"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "CVL-865",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 154,
      "start_date": "2020-01-27",
      "completion_date": "2024-05-21",
      "has_results": true,
      "last_update_posted_date": "2025-05-30",
      "last_synced_at": "2026-10-05T05:52:00.646Z",
      "location_count": 37,
      "location_summary": "Little Rock, Arkansas • Downey, California • Loma Linda, California + 33 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Valencia",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04244175"
    }
  ]
}